Your browser doesn't support javascript.
loading
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
Mennitto, Alessia; Zattarin, Emma; Di Maio, Massimo; Bimbatti, Davide; De Giorgi, Ugo; Buti, Sebastiano; Santini, Daniele; Casadei, Chiara; Sorarù, Mariella; Messina, Carlo; Mucciarini, Claudia; Di Lorenzo, Giuseppe; Roviello, Giandomenico; Buttigliero, Consuelo; Stellato, Marco; Sepe, Pierangela; Claps, Melanie; Guadalupi, Valentina; Ottini, Arianna; Pignata, Sandro; De Braud, Filippo G; Verzoni, Elena; Procopio, Giuseppe.
Affiliation
  • Mennitto A; Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy.
  • Zattarin E; Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy.
  • Di Maio M; Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy.
  • Bimbatti D; Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto Iov Irccs, Padua, Italy.
  • De Giorgi U; Department of Medical Oncology, Istituto Scientifico Romagnolo per Lo Studio E La Cura Dei Tumori (Irst), Irccs, Meldola, Italy.
  • Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Santini D; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
  • Casadei C; Department of Medical Oncology, Istituto Scientifico Romagnolo per Lo Studio E La Cura Dei Tumori (Irst), Irccs, Meldola, Italy.
  • Sorarù M; Medical Oncology, Camposampiero Hospital, Camposampiero (Padua), Italy.
  • Messina C; Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
  • Mucciarini C; Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy.
  • Di Lorenzo G; Oncology Unit, Andrea Tortora Hospital, ASL Salerno, Pagani, Italy.
  • Roviello G; Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
  • Buttigliero C; Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
  • Stellato M; Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy.
  • Sepe P; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
  • Claps M; Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy.
  • Guadalupi V; Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy.
  • Ottini A; Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy.
  • Pignata S; Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy.
  • De Braud FG; Department of Urology and Gynecology, Istituto Nazionale Tumori Irccs Fondazione "G. Pascale", Naples, Italy.
  • Verzoni E; Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy.
  • Procopio G; Oncology and Hemato-Oncology Department, University of Milan, Milan, Italy.
Expert Rev Anticancer Ther ; 22(1): 115-121, 2022 Jan.
Article in En | MEDLINE | ID: mdl-34738499
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Expert Rev Anticancer Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Expert Rev Anticancer Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article Affiliation country: Country of publication: